Search Results
Your search for ,foR matches 32412 pages
Showing 15801 - 15850ESMO 2018: Small Study of Preoperative Nivolumab Plus Ipilimumab in dMMR Colon Cancer
Neoadjuvant treatment with a combination of the immune checkpoint inhibitors nivolumab (Opdivo) and ipilimumab (Yervoy) achieved major pathological responses in mismatch repair–deficient (dMMR) early-stage colon cancers, according to results reported by Chalabi et al at the European...
ESMO 2018: HOBOE-2: Zoledronic Acid in Premenopausal Hormone Receptor–Positive Early Breast Cancer
Adjuvant treatment with zoledronic acid, plus hormonal therapy with the aromatase inhibitor letrozole, significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor–positive early breast cancer, according to results reported by Perrone et al...
ESMO 2018: CheckMate 067: 4-Year Follow-up of Nivolumab Plus Ipilimumab in Advanced Melanoma
As reported in The Lancet Oncology and at the European Society for Medical Oncology 2018 Congress by Hodi et al, the 4-year follow-up of the phase III CheckMate 067 trial has shown a continued overall survival benefit with first-line nivolumab (Opdivo) plus ipilimumab (Yervoy) or nivolumab alone vs ...
2018 ASTRO: SPPORT Trial: ADT With or Without Pelvic Lymph Node Radiation in Prostate Cancer
The first report of a large international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term androgen-deprivation therapy (ADT) to standard treatment...
Novel Statistical Model in Estimating the Risk of Breast Cancer Recurrence
Although population-based cancer registries data are useful in tracking and reporting the evolving burden of cancer in the population, the information they capture reflects the outcomes of diagnosis and death, regardless of whether the death is due to the disease or to other causes, and not data on ...
Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphoma
In a single-institution study reported in the Journal of Clinical Oncology, Alderuccio et al found that not achieving complete remission (CR) after initial treatment, elevated lactate dehydrogenase (LDH), and more than four nodal sites at marginal zone lymphoma diagnosis are predictive of...
2018 ASTRO: IROCK: Stereotactic Ablative Radiotherapy for RCC in Patients With One Kidney
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those with two, according to an analysis of an international data set presented by Correa et al at the 60th Annual Meeting of the American Society for...
2018 ASTRO: SABR-COMET: Stereotactic Ablative Radiation Therapy for Oligometastatic Tumors
In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can increase survival in patients with oligometastatic tumors. These findings were presented by Palma et al in the plenary session at the 60th Annual ...
IASLC Issues Statement on Lung Cancer Screening With Low-Dose Computed Tomography
The International Association for the Study of Lung Cancer (IASLC) recently issued a statement on lung cancer screening with low-dose computed tomography (CT) based on the results of the Dutch-Belgian NELSON lung cancer screening trial presented at the IASLC 19th World Conference on Lung Cancer...
2018 ASTRO: Overall Survival With Local Consolidative Therapy in Oligometastatic NSCLC
Adding radiation therapy or surgery to systemic therapy for patients with stage IV lung cancer whose cancer has spread to a limited number of sites can significantly extend overall survival, according to new results from a multicenter, randomized, controlled phase II study. The findings were...
2018 ASTRO: Liquid Biopsy in HPV-Associated Oral Cancer Surveillance
A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings were presented by...
2018 ASTRO: Radiation After Breast-Conserving Surgery in 'Good-Risk' DCIS
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery, but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report. These 12-year follow-up data from the only prospective,...
Cost-Effectiveness of First-Line Brentuximab Vedotin Plus Chemotherapy in Hodgkin Lymphoma
In a cost-effectiveness analysis reported in the Journal of Clinical Oncology, Huntington et al found that the cost of brentuximab vedotin (Adcetris) would need to be reduced in order for the combination of the agent with chemotherapy in first-line treatment of stage III or IV Hodgkin lymphoma to...
Long-Term Results of Sequence of Hormonal Therapy Plus Whole-Pelvic or Prostate-Alone Radiotherapy in Prostate Cancer
In long-term follow-up of the phase III NRG/RTOG 9413 study reported in The Lancet Oncology by Roach et al, neoadjuvant hormonal therapy (NHT) plus whole-pelvic radiotherapy (WPRT) and prostate-only radiotherapy (PORT) plus adjuvant hormonal therapy (AHT) were associated with the highest rates of...
Michael Soike, MD, on Brain Metastases: Radiosurgery vs Radiotherapy
Michael Soike, MD, of Wake Forest University Medical Center, discusses results from a large multicenter study that suggests salvage stereotactic radiosurgery leads to improved overall survival compared with whole-brain radiotherapy for patients with progressive brain metastases (Presentation 296 in ...
David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial
David Palma, MD, PhD, of the London Health Sciences Centre, discusses study findings on improvement in survival following stereotactic ablative radiation for oligometastatic tumors (Presentation 5 in PL 01).
2018 ASTRO: FAST Trial Finds Long-Term Side Effects Similar for Once-Weekly and Conventional Breast Radiation Therapies
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer, larger individual radiation doses experienced similarly low rates of late-onset side effects as those undergoing conventional radiation therapy. Findings from the...
2018 ASTRO: Impact of MGMT Gene Expression on Overall Survival in Patients With Anaplastic Glioma
A phase III trial revealed that elevated MGMT gene expression is independently associated with worse overall survival for patients with anaplastic grade III gliomas. These findings were presented by Fleming et al at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) and...
2018 ASTRO: Combined Radiation and Cisplatin in HPV-Related Head and Neck Cancer
A phase III trial has determined that cisplatin chemotherapy combined with radiation therapy showed high amounts of activity in human papillomavirus (HPV)-related head and neck cancer. Findings from NRG-RTOG 1016 were presented by Trotti et al the 60th Annual Meeting of the American Society for...
2018 ASTRO: Radiation Therapy Outcomes in African American Patients With Prostate Cancer
A new analysis of genetic data from a large prospective registry and clinical data from several randomized trials indicates that African American patients may have comparatively higher cure rates when treated with radiation therapy than Caucasian patients. The study, which is the first report...
FDA Approves Levoleucovorin for Treatment in Osteosarcoma, Colorectal Cancer
The U.S. Food and Drug Administration (FDA) recently approved levoleucovorin (Khapzory) injection, a folate analog, for three indications: rescue after high-dose methotrexate therapy in patients with osteosarcoma; diminishing the toxicity associated with overdosage of folic acid...
Analgesic Use and Risk of Ovarian Cancer
In an analysis of data from two Nurses’ Health Study cohorts reported in JAMA Oncology by Barnard et al, use of low-dose but not standard-dose aspirin was associated with reduced risk of epithelial ovarian cancer, whereas use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs)...
Analysis of Prognostic Value of Postinduction PET Response After First-Line Immunochemotherapy for Follicular Lymphoma
In an analysis of the phase III GALLIUM trial reported in The Lancet Oncology, Trotman et al found that end-of-induction fluorodeoxyglucose positron-emission tomography (PET) after first-line immunochemotherapy appeared to better predict treatment outcomes than contrast-enhanced computed tomography ...
ESMO 2018: First-Line Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Pembrolizumab (Keytruda) improved survival in patients with head and neck cancer that has recurred or metastasized in the KEYNOTE-048 trial, according to late-breaking results from the study reported by Burtness et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract...
ESMO 2018: Cetuximab vs Cisplatin in Patients With HPV-Positive Oropharyngeal Cancer Receiving Radiotherapy
Patients with human papillomavirus (HPV)-positive throat cancer responded better to chemoradiotherapy than to cetuximab (Erbitux) with radiotherapy, according to late-breaking research reported by Mehanna et al at the European Society for Medical Oncology (ESMO) 2018 Congress (Abstract LBA9_PR)....
Philip J. DiSaia, MD, Former President, Society of Gynecologic Oncology, American Board of Obstetrics & Gynecology, Dies at 81
The grandson of Italian immigrants, Philip J. DiSaia was born on August 14, 1937, in Providence, Rhode Island. He earned his Bachelor’s in Science at Brown University and his MD at Tufts University. Upon the advice of his mentor in medical school, Dr. DiSaia obtained 2 years of general surgery...
Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma
In a study reported in JAMA Oncology, Maria I. Carlo, MD, of the Department of Medicine, Memorial Sloan Kettering Cancer, and colleagues found a high prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma (RCC). In this cohort study,...
Meta-analysis of Patients With Early Kidney Cancer Treated With Robotic Partial Nephrectomy
For patients with early kidney cancer, surgically removing a portion of the kidney instead of the whole organ is often a preferred treatment, because the procedure can effectively remove tumors while preserving kidney function. But when it comes to the best surgical approach—robotic, laparoscopic, ...
Sunitinib vs Nephrectomy Followed by Sunitinib in Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by...
Many Patients With Early-Stage Follicular Lymphoma May Not Receive Guideline-Recommended Radiation Therapy
Radiation therapy for early-stage follicular lymphoma “is underused,” Joanna C. Yang, MD, MPH, and Joachim Yahalom, MD, declared in a recent editorial in the Journal of Clinical Oncology.1 This underuse of radiation therapy can result in overtreatment with systemic therapies or overconfidence in...
Children’s Hospital of Philadelphia–Led Collaboration Launches First Childhood Disease Research Portal
The Gabriella Miller Kids First Data Resource Center, a collaborative effort supported by the National Institutes of Health (NIH) Common Fund, announced the launch of its new Data Resource Portal to help accelerate the discovery of precision-based treatments for pediatric disorders, thanks to a...
Gastric Cancer Foundation Introduces Online Clinical Trials Navigator
The Gastric Cancer Foundation launched its new website this month and introduced an online clinical trials navigator to help patients more easily identify clinical trials matched with their specific diagnosis, stage, and treatment history. A special grant from Stupid Strong Charitable Foundation, a ...
Biden Cancer Initiative Supports Lynch Syndrome Research
In 2016, AliveAndKickn launched the HEROIC Registry, a patient-driven registry to collect real world and genomic data on patients with Lynch syndrome globally. Recently, AliveAndKickn started a collaboration with the University of California, San Francisco, to launch The HEROIC Mosaic Research...
Friends of Cancer Research Launches Tumor Mutational Burden Harmonization Project
The Friends of Cancer Research (Friends) recently announced the launch of phase II of its tumor mutational burden Harmonization Project, as the research team finalizes data collected from phase I in silico analysis. “Recent data show a role for [tumor mutational burden] in identifying patients...
Exercise Therapy for Symptom Management and Treatment in Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Although physical activity is associated with many positive outcomes in the general population,...
Humbled by Challenges, Renowned Hematologist Kanti R. Rai, MD, Recalls a Rich Career
For this installment of the Living a Full Life series, guest editor, Jame Abraham, MD, interviewed Kanti R. Rai, MD, Professor of Medicine at the Karches Center for Oncology Research, Feinstein Institute for Medical Research, Manhasset; Professor of Medicine at Zucker School of Medicine at...
I’m Not Dying of Cancer: I’m Living With Cancer
I’m a psychiatrist, so I don’t say this lightly: receiving a diagnosis of stage IV gastric adenocarcinoma made me insane. I had remembered the horrible deaths due to abdominal cancer I had seen during my medical training and was terrified that would be my fate as well. I knew from looking at the...
Big Data and Breast Cancer: Moving the Field Forward Through Comprehensive Analysis
To gain further insight into, among other things, optimizing big data and the latest on hormonal breast cancer treatment, The ASCO Post recently spoke with pioneering oncologist Christopher C. Benz, MD, a breast cancer specialist and Director of the Cancer & Developmental Therapeutics Program, ...
Has the Promise of Precision Medicine Been Oversold?
Recently, the term “personalized medicine” in oncology care has been overtaken by the more contemporary concept of “precision medicine.” According to the National Research Council of the National Academies of Science, Engineering, and Medicine, the newer terminology shifts the focus to improving...
Everolimus Tablets for Oral Suspension for Tuberous Sclerosis Complex–Associated Partial-Onset Seizures
On April 10, 2018, the U.S. Food and Drug Administration approved everolimus tablets for oral suspension (Afinitor Disperz) for the adjunctive treatment of adult and pediatric patients aged ≥ 2 years with tuberous sclerosis complex–associated partial-onset seizures.1,2 Tuberous sclerosis complex is ...
Overcoming Long-Term Health and Economic Impact of Cancer on Young Adult Survivors
A pair of studies showcased the potentially devastating long-term health and financial consequences cancer has on adult survivors of childhood cancer compared with other adults, as well as survival disparities based on health insurance status.1,2 Despite increasing survival rates among the more...
On the Frontier of Breast Cancer Research With Joyce A. O’Shaughnessy, MD
Nationally regarded breast cancer researcher and clinician Joyce A. O’Shaughnessy, MD, was born in upstate New York, just outside of Albany, where she attended grade school before her family moved to Beverly, Massachusetts, a suburban town 26 miles from Boston, where her family’s roots were....
AMA Awards Research Grants to Honor Women in Medicine
Each September, the American Medical Association (AMA) recognizes influential female physician leaders in honor of Women in Medicine Month. To showcase the accomplishments of these leaders, the AMA Women Physicians Section (WPS) and the AMA Foundation announced the winners of the 2018 Joan F....
Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights
Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targeted treatment for early stage NSCLC, combining immunotherapy for surgically resectable disease, and immunotherapy for...
Activity of Antibody-Drug Conjugate Telisotuzumab Vedotin in c-Met–Positive Advanced NSCLC
In a phase I study reported in the Journal of Clinical Oncology, Strickler et al found evidence of activity of the antibody-drug conjugate telisotuzumab vedotin in non–small cell lung cancer (NSCLC) overexpressing c-Met. The agent combines the anti–c-Met monoclonal antibody...
ESMO 2018: Survival Results From STAMPEDE: Local Radiotherapy in Newly Diagnosed Metastatic Prostate Cancer With Low Disease Burden
Radiotherapy to the prostate improved overall survival in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden, but not in those with higher burden of disease, according to results from a preplanned analysis of a large comparison study reported by Parker et...
ESMO 2018: JAVELIN Renal 101: Avelumab Plus Axitinib in Previously Untreated Renal Cell Carcinoma
A combination of the immune checkpoint blocker avelumab (Bavencio) plus the tyrosine kinase inhibitor axitinib (Inlyta) improved progression-free survival (PFS) in previously untreated patients with advanced renal cell carcinoma (RCC) in the phase III JAVELIN Renal 101 study, according to results...
ESMO 2018: SOLO-1: Olaparib Maintenance Extends Progression-Free Survival in BRCA1/2-Mutated Advanced Ovarian Cancer
Two-year maintenance therapy with olaparib (Lynparza), a poly ADP-ribose polymerase (PARP) inhibitor, led to a substantial improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation, results from the phase III SOLO-1 trial...
Multiple Financial Barriers Impede Patient Participation in Cancer Clinical Trials, According to New ASCO Policy Statement
ASCO issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. The policy statement stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic, racial, geographic, age,...
Largest ASCO RCF Annual Meeting to Date Facilitated Meaningful Discussion on Conducting Clinical Trials
The ASCO Research Community Forum (RCF) 2018 Annual Meeting brought together 165 physician investigators and research staff from 34 states across the country—its largest meeting to date—to discuss contemporary challenges and develop creative solutions in conducting and managing clinical trials. The ...
